Home / Brand Stories / JFL Life Sciences Limited SME IPO – NSE Emerge opens on 25th August 2022
BRAND POST

JFL Life Sciences Limited, engaged in the business of manufacturing pharmaceutical products having experience of more than a decade, is all set to raise 1,816.58 Lakhs through an initial public offering (IPO). The issue opens on the 25th of August and will be listed on NSE Emerge.

The public issue of JFL Life Sciences Limited is 29,78,000 equity shares of Face Value 10 each (“EQUITY SHARES") for cash for 61/- per equity share (including a securities premium of 51/- per equity share) (the issue price) aggregating 1,816.58 LACS of the issue. 1,50,000 equity shares aggregating to 91.50 Lakhs will be reserved for the market maker (“Market Maker Reservation Portion"). The issue, less the Market Maker Reservation Portion, i.e., issue of 28,28,000 equity shares of Face Value of 10/- EACH at an issue price of 61/- per equity share, aggregating to 1,725.08 Lakhs, which is hereinafter referred to as “The Net Issue". The issue and the Net Issue will constitute 27.08% AND 25.71%, respectively, of the post-issue, paid-up equity share capital of the company. The company will list at NSE Emerge. The Lead manager of the issue is GYR Capital Advisors Pvt Ltd, and the Registrar of the issue is KFin Technologies Ltd. The issue opens on the 25th of August and will close on the 30th of August, 2022 and will subsequently be listed on NSE Emerge.

The company intends to utilize the proceeds of the Issue to meet the following objectives:

1. Repayment of secured and unsecured loans

2. Funding the working capital requirements of the company

3. General Corporate Purposes

JFL Life Sciences Limited is engaged in the business of manufacturing pharmaceutical products. Their product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam), solid oral dosage forms and tablets and capsules (general), Solid Oral Dosage Forms and Oral rehydration solutions (ORS). With a market presence in pan India, products of JFL supply to 10 developed and developing countries throughout the World. To maintain its competitiveness and to further the cause of health care, JFL has laid a strong R&D foundation and an FDA-approved state-of-the-art manufacturing facility near Ahmedabad.

The Company has registered their products to be manufactured in various countries like the sovereign of Kenya, Nigeria, Yemen & Myanmar. Few of their products are also registered with Ukraine, Uzbekistan, and Kazakhstan as well. This also makes them a ‘one-stop-shop’ service provider for catering to all of the customer’s needs domestically as well as internationally.

The promoters, Mr. SmiralAshwinbhai Patel and TejalSmiralbhai Patel, are actively involved in the day-to-day business of the company and are the guiding force behind the strategic decisions for the Company. Their management team and other key management personnel are well qualified and have extensive industry expertise, and have been responsible for the operational growth.

Proposed IPO Snapshot
View Full Image
Proposed IPO Snapshot

Disclaimer: This article is a paid publication and does not have journalistic/editorial involvement of Hindustan Times. Hindustan Times does not endorse/subscribe to the content(s) of the article/advertisement and/or view(s) expressed herein. Hindustan Times shall not in any manner, be responsible and/or liable in any manner whatsoever for all that is stated in the article and/or also with regard to the view(s), opinion(s), announcement(s), declaration(s), affirmation(s) etc., stated/featured in the same.

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout